drug · antibody
rinatabart sesutecan
Phase 3updated 6mo agoby Genmab AS🔗 ChEMBL
Phase 3community read0 votes
Antibody drug with a maximum clinical stage of Unknown, with 1 investigational indication.
indications
indications
NSCLC
all catalysts(0)
nothing on the calendar yet
News(8)
- Genmab soars to record highs after cancer drug succeeds in key trialThe drugmaker’s market value swelled by more than $7 billion on findings suggesting a recently-acquired medicine could become a new treatment standard for a form of head and neck cancer.biopharma_dive · 16d ago
- Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readoutAnalysts hailed the Phase 3 head and neck cancer results as a big victory for an asset central to Genmab’s growth plans.biospace · 17d ago
- Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readoutAnalysts hailed the Phase 3 head and neck cancer results as a big victory for an asset central to Genmab’s growth plans.biospace · 17d ago
- Genmab's $8B Merus bet delivers as bispecific combo halves risk of death in phase 3Capping off a busy few days in Spain, Genmab reported results from the first interim analysis of a phase 3 trial showing that adding its bispecific antibody petosemtamab to Merck & Co.'s Keytruda c…fiercebiotech · 17d ago
- Genmab’s ADC beats survival expectations in Phase 3 ovarian cancer trialExtending both progression-free and overall survival, Genmab’s Rina-S “sets a high bar for future competition” in a market served by AbbVie, analysts said.biospace · 19d ago
- Epkinly data only one of Genmab's make-or-break readouts ahead of steep sales erosionBracing for patent losses on its cornerstone product Darzalex, Genmab has bet its future on three cancer programs that will deliver pivotal readouts in quick succession.biospace · 26d ago
- ESMO: Lilly touts 79% ADC response rate in competitive ovarian cancer spaceEli Lilly has shared phase 1 data on an antibody-drug conjugate in platinum-sensitive ovarian cancer, shedding light on the company’s chances of competing for a market targeted by rivals including…fiercebiotech · 27d ago
- Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s ElahereGenmab has linked an antibody-drug conjugate to a median progression-free survival of 9.5 months, leading TD Cowen analysts to hail the asset as “clearly superior” to AbbVie’s Elahere.fiercebiotech · 1mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that